Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DexCom’s continuous glucose monitor

This article was originally published in The Gray Sheet

Executive Summary

DexCom plans a limited launch of Seven, its next-generation, seven-day STS continuous glucose monitor, at the end of the second quarter followed by a "more robust launch" in the third quarter, the company announces May 31 upon the device's FDA approval. The original STS continuous monitor was approved in March 2006, requiring glucose sensors to be replaced every three days (1"The Gray Sheet" May 22, 2006, p. 17). DexCom says it will hold a conference call "to discuss the approval and product launch plans in more detail at a later date"...

You may also be interested in...



Dexcom Makes Final Preparations On Seven-Day Glucose Monitor Submission

Dexcom plans to submit a PMA supplement for its seven-day STS continuous glucose monitoring system by the end of June

IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel